Abstract
We aimed to examine past advance care planning (ACP) in U.S. older adults across different sociodemographic characteristics and cognition levels. We established the baseline trends from 10 years ago to assess if trends in 2024 have improved upon future data availability. We considered two legal documents in the Health and Retirement Study 2014 survey as measures for ACP: a living will and durable power of attorney for healthcare (DPOAH). Logistic regression models were fitted with outcome variables (living will, DPOAH, and both) stratified by cognition levels (dementia/impaired cognition versus normal cognition). Predictor variables included age, gender, ethnicity, race, education, marital status, rurality, everyday discrimination, social support, and loneliness. Age, ethnicity, race, education, and rurality were significant predictors of ACP (having a living will, DPOAH, and both the living will and DPOAH) across cognition levels. Participants who were younger, Hispanic, Black, had lower levels of education, or resided in rural areas were less likely to complete ACP. Examining ACP and its linkages to specific social determinants is essential to understanding disparities and educational strategies needed to facilitate ACP uptake among different population groups. Accordingly, this study aimed to examine past ACP disparities in relation to specific social determinants of health and different cognition levels. Future studies are required to evaluate whether existing disparities have improved over the last 10 years when 2024 data is released. Addressing ACP disparities among diverse populations, including racial and ethnic minorities with reduced cognition levels, is crucial for enhancing health equity and access to care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Alzheimers Association (24AARG-D-1242910) Carolina Center on Alzheimers Disease and Minority Research (CCADMR) National Institute on Aging P30AG059294-04 Sub-award no: 22-4642
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clemson University Institutional Review Board exempted the study protocols (IRB Number: IRB2021-0720).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Juanita-Dawne R. Bacsu, PhD, E-mail: juanita.bacsu{at}usask.ca
Sophia Z. Shalhout, PhD, Email: Sophia_Shalhout{at}meei.harvard.edu
Morteza Sabet, PhD, Email: ssabet{at}clemson.edu
Delaram Sirizi, DVM, MPH, Email: darjoma{at}clemson.edu
Matthew Lee Smith, PhD, MPH, CHES, Email: matthew.smith{at}tamu.edu
Swann Arp Adams, MS, PhD, FACE, E-mail: swann.adams{at}sc.edu
Author name correction. An author listed in the original version had the last name duplicated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
